|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 2985 Drew Street |
Address2 |
|
| City | Clearwater |
State | FL |
Zip Code | 33759 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Clearwater |
State | FL |
Zip Code | 33759 |
Country | USA |
|
5. Senate ID# 400855514-12
|
||||||||
|
6. House ID# 418910000
|
||||||||
| TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: John Learn |
Date | 7/19/2023 4:47:07 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Met with HRSA to discuss current concerns around the 340B drug pricing program, specifically pandemic era flexibility in offsite departments being 340B eligible prior to a cost report being filed.
Submitted comment letters for Proposed Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2024 Rates [CMS-1785-P], and Medicare Program; Medicare Disproportionate Share Hospital (DSH) Payments: Counting Certain Days Associated With Section 1115 Demonstrations in the Medicaid Fraction Proposed Rule CMS-1788-P. We also submitted a statement for the record to the House Ways and Means Committee on the subject of the Oversight Subcommittee Hearing on Tax-Exempt Hospitals and the Community Benefit Standard held on April 26th, 2023.
Met with Florida Congressional members and staff, Rep. Bilirakis, Rep. Castor, Rep. L Lee, Rep. Luna, Sen. Rubio, Rep. V Buchanan, Rep. S. Franklin, Sen. Scott, and Ways and Means Committee staff to discuss workforce issues for hospitals, including the graduate medical education program (Resident Physician Shortage Reduction Act of 2023 (H.R. 2389)) and visa needs (Healthcare Workforce Resilience Act of 2023 (HWRA)). Also discussed stress points with the 340B drug pricing program in terms of additional regulatory actions, and community benefit activities within the larger context of hospital financial constraints.
Met with Florida Congressional members and staff for Reps. Castor and Luna, Committee staff from Senate Finance and HHS Representatives to discuss integration of behavioral health services into the traditional healthcare setting, and issues affecting the behavioral health workforce.
Met with Florida Congressional members and staff for Reps. Castor, Luna, Bilirakis, L. Lee and S. Franklin, and Senators Rubio and Scott. We discussed stress points for children's hospitals, such as pediatric drug and supply shortages that can be remedied with greater transparency from manufacturers as well as additional incentives to produce domestically. We also discussed the need for greater GME funding to states such as Florida (Resident Physician Shortage Reduction Act of 2023 (H.R. 2389)).
BayCare will continue to advocate for better payment rates in Medicare for the various proposed rules that impact payment to our doctors and hospitals.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Learn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
In the comment letter submitted for Medicare Disproportionate Share Hospital (DSH) Payments: Counting Certain Days Associated With Section 1115 Demonstrations in the Medicaid Fraction Proposed Rule CMS-1788-P we advocated that by unnecessarily reducing funding for states that operate uncompensated care funding pools, CMS would put a strain on resources at community hospitals that rely on those resources which would result in less proactive programming targeting community health improvement and overall potentially a decline in quality of care/outcomes.
In the Proposed Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2024 Rates [CMS-1785-P] comment letter, BayCare advocated for greater level of payment to providers given the current financial constraints in healthcare in order to preserve and maintain the high level of care afforded to patients. BayCare also applauded the change of severity level designation for diagnosis codes by describing homelessness from non-complication or comorbidity to complication or comorbidity, noting the impact these factors have on resource utilization and in turn increasing payment to provide greater support to this population by deepening wrap around services available.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Learn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Discussed current activity in Congress on 340B and the lack of accountability on drug manufacturers as well as the programming BayCare provides the community with the 340B savings. These programs include the Medication Assistance Program to ensure all in our community have access to the prescription drugs they require (we take referrals from anyone, not just BayCare patients/providers) and the Pharmacy Transition of Care team that helps improve medication adherence and transition/care coordination for those returning home with various prescriptions.
We also discussed specific challenges regarding rule changes made in offsite facilities not being immediately alongside the conclusion of the PHE.
17. House(s) of Congress and Federal agencies Check if None
Centers For Medicare and Medicaid Services (CMS), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Learn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | 2985 Drew St |
||||||
| City | CLEARWATER |
State | FL |
Zip Code | 33759 |
Country | USA |
21. Client new principal place of business (if different than line 20)
| City | CLEARWATER |
State | FL |
Zip Code | 33759 |
Country | USA |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
| BayCare Health System |
|
|
||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |